Search

Your search keyword '"Proteases -- Planning"' showing total 5 results
Start Over Descriptor "Proteases -- Planning" Topic business, international
5 results on '"Proteases -- Planning"'

1. Catalyst Biosciences Announces Key Leadership Changes in its Ongoing Transition to an Integrated Protease Medicines Company

Subjects
Novo Nordisk A/S -- Officials and employees, Executives -- Planning, Proteases -- Planning, Blood coagulation factors -- Planning, Hemophilia, Pharmaceutical industry -- Officials and employees, Company business planning, Business, international, Law
Abstract

(GlobeNewswire) - Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it has promoted Grant Blouse, Ph.D., to chief scientific officer and Tom Knudsen, DVM, Ph.D., to senior vice president, corporate development. [...]

Published
2021

2. Omeros Investigational New Drug Application for OMS906 Cleared by FDA

Subjects
United States. Food and Drug Administration -- Planning, Monoclonal antibodies, Proteases -- Planning, Biological products -- Planning, Company business planning, Business, international, Law
Abstract

Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug Administration (FDA). OMS906 is [...]

Published
2020

3. Selva raises $3m to develop novel antiviral against Covid-19

Subjects
Sofosbuvir -- Planning, Proteases -- Planning, COVID-19, Company business planning, Company financing, Business, international, Law
Abstract

Selva is planning to use the $3m it has raised in a Series A round to support the early clinical development of its lead candidate SLV213 for Covid-19. SLV213 is [...]

Published
2020

4. Omeros Updates on Investigational NDA for OMS906 Cleared by FDA

Subjects
United States. Food and Drug Administration -- Planning, Monoclonal antibodies, Proteases -- Planning, Company business planning, Business, Business, international, Telecommunications industry
Abstract

Omeros Corp. reported that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug Administration (FDA). According to a [...]

Published
2020

5. Cortexyme gathers $76M to fund efficacy study of antibiotic for Alzheimers

Subjects
Pfizer Inc. -- Officials and employees -- Planning, Bacterial infections, Antibiotics -- Planning, Protease inhibitors -- Planning, Proteases -- Planning, Pharmaceutical industry -- Officials and employees -- Planning, Alzheimer's disease, Company business planning, Business, international
Abstract

Alzheimers disease startup Cortexyme was able to round up $76 million in funding for a potentially first-in-class treatment, while other companies are looking to move away from the field. The [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results